Objective       To observe the efficacy and safety of rasagiline mesylate in levodopa-treated patients with idiopathic Pakinson’s disease and motor fluctuations.        Methods       A total 44 Pakinsonian patients with motor fluctuations receiving levodopa for over 8 weeks were recruited in a single-center

16-week

randomized

double-blind

parallel-controlled trial in our department from January 2012 to September 2013. The efficacy of rasagiline mesylate was assessed using the patient’s diary card and the Unified Parkinson

’s Disease Rating Scale (UPDRS) score. The safety was assessed on the basis of adverse events

blood pressure

pulse

laboratory measurements and ECG recordings.       Results       There were 1 case from rasagiline mesylate-treated group and 2 from placebo-treated group not completed the 16-week treatment. Rasagiline mesylate decreased the mean “off” time from 3.18±0.65 h/d in base-line to 1.90±0.85 h/d

and increased the “on” time from 10.74±1.44 h/d in base-line to 12.05±1.72 h/d in week 16 at the end of treatment

with significant improvement in comparison to the placebo-treated patients (

P

0.05). Rasagiline mesylate treatment also improved UPDRSⅡ-Ⅳ scores from 64.00±16.30 in base-line to 45.80±11.54 and all item scores. No adverse event or reaction was observed in rasagiline mesylate-treated group.       Conclusion       Rasagiline mesylate is an effective and safe extender of levodopa treatment for Pakinsonian patients with motor fluctuations.